Craig H. Moskowitz

Hartford Hospital — United States

Medicine · Health Sciences

72h-index22.7kcitations534works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(451), Chronic Lymphocytic Leukemia Research(136), CNS Lymphoma Diagnosis and Treatment(111), Viral-associated cancers and disorders(103), Lung Cancer Treatments and Mutations(95)

Publications532 total

Supplementary Data 2 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
2025Open Access
Supplementary Data 1 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
2025Open Access
Supplementary Tables from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
2025Open Access
Supplementary Figures from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
2025Open Access
Adherence to the 2018 world cancer research fund/American institute for cancer research cancer prevention recommendations and mortality among blood cancer survivors
Blood·2025Open Access
Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial
Blood·2025Open Access
First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation
Blood·2025
Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma
Blood·2025Open Access
Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The life-l study
Blood·2025Open Access
Deep Learning–Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 Trial
JCO Clinical Cancer Informatics·2025
129 | PEMBROLIZUMAB AND RADIATION THERAPY ALONE AS AN ALTERNATIVE TO TRANSPLANT FOR LOCALIZED FAILURE AFTER CHEMOTHERAPY IN HODGKIN LYMPHOMA: A MULTICENTER PHASE II STUDY
Hematological Oncology·2025Open Access
74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMA
Hematological Oncology·2025· 3 citedOpen Access
260 | UPDATED ANALYSIS OF A PHASE 2 MULTICENTER STUDY OF THE LONCASTUXIMAB IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA DEMONSTRATES HIGH RATE OF COMPLETE RESPONSES
Hematological Oncology·2025Open Access
Characterizing unmet supportive care needs in diverse adolescent and young adult cancer survivors.
Journal of Clinical Oncology·2025
<scp>PET</scp>/<scp>CT</scp> in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma
American Journal of Hematology·2025· 4 citedOpen Access
F-116 | Comparison of Perclose® Vascular Closure Device vs Figure of Eight Stitch for Large Bore Venous Access Hemostasis After Percutaneous Cardiovascular Procedures: A Meta-Analysis of Comparative Studies
Journal of the Society for Cardiovascular Angiography & Interventions·2025Open Access
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis
Leukemia & lymphoma/Leukemia and lymphoma·2025· 2 cited
Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
The Lancet Haematology·2024· 20 cited
Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
Blood·2024· 2 cited
Gene Expression-Based Classifier Reclassifies Burkitt Lymphoma, HGBL NOS, DLBCL NOS, and Double/Triple Hit Lymphomas into Subtypes with More Uniform Mutational and Microenvironment Landscapes and Treatment Response
Blood·2024
page 1 of 27Next →

Frequent Co-authors

Andrew D. Zelenetz(26), David J. Straus(17), Ariela Noy(17), Carol S. Portlock(16), Joachim Yahalom(16), Paul A. Hamlin(13), Alison J. Moskowitz(12), Steven M. Horwitz(11), Stephen D. Nimer(10), Matthew J. Matasar(9), Heiko Schöder(8), Jing Qin(7), Tarun Kewalramani(7), Nancy L. Bartlett(6), Margaret A. Shipp(6), Owen A. O’Connor(6), Anas Younes(5), Pier Luigi Zinzani(5), Philippe Armand(5), John Radford(5)